Clinical overview of saxagliptin for Type 2 diabetes management

Expert Review of Endocrinology and Metabolism

Volumn 5, Issue 6, 2010, Pages 809-823

  Rosenstock, Julio ^a  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

Author keywords

dipeptidyl peptidase 4; DPP 4 inhibitor; GLP 1; glucagon like peptide 1; glycated hemoglobin; HbA1c; incretin; metformin; saxagliptin; sulfonylurea; thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; ALUMINUM HYDROXIDE; DIGOXIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; FAMOTIDINE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; INSULIN; KETOCONAZOLE; LINAGLIPTIN; METFORMIN; OMEPRAZOLE; PIOGLITAZONE; PLACEBO; RIFAMPICIN; SAXAGLIPTIN; SIMETHICONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DYSPEPSIA; ENZYME INHIBITION; GASTROENTERITIS; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IC 50; INFLUENZA; INSULIN RELEASE; LIMB PAIN; MAXIMUM ALLOWABLE CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SINUSITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 78649363663     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.10.60     Document Type: Review

References (52)

1. Ong KL, Cheung BMY, Wong LYF et al. Prevalence, treatment, and control of diagnosed diabetes in the U.S. national health and nutrition examination survey 1999-2004. Ann. Epidemiol. 18(3), 222-229 (2008).
2. Levy P. The current unmet need in Type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Postgrad. Med. 121(3 Suppl. 1), 7-12 (2009).
3. ®, package insert. Amylin Pharmaceuticals, Inc., San Diego, CA, USA.
4. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the national health and nutrition examination survey. Diabetes Care 29(3), 531-537 (2006).
5. Edelman SV, Henry RR. Diagnosis and Management of Type 2 Diabetes (Volume 8). Professional Communications Inc., NY, USA (2007)
6. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes. 32(Suppl. 1), S1-S201 (2008).
7. Rodbard H W, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 15(6), 541-559 (2009).
8. Pollack M, Chastek B, Williams SA. Impact of treatment complexity on adherence and glycemic control: an analysis of oral anti-diabetic agents. Presented at: International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting. Orlando, FL, USA, 16-20 May 2009.
9. Thomas L, Eckhardt M, Langkopf E et al. (R)-8-(3-amino-piperidin-1-yl)-7- but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther. 325(1), 175-182 (2008).
10. Henry R, Smith S, Schwartz S et al. p-cell stimulation by saxagliptin in patients with Type 2 diabetes. Diabetes 58(Suppl. 1), 447-P (2009).
11. Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 31(1), 30-35 (2008).
12. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of Type 2 diabetes mellitus. Curr. Opin. Endocrinol. Diabetes Obes. 14(2), 98-107 (2007).
13. Rosenstock J. Refecting on Type 2 diabetes prevention: more questions than answers! Diabetes Obes. Metab. 9(Suppl. 1), 3-11 (2007).
14. Frederich R, Alexander JH, Fiedorek FT et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for Type 2 diabetes. Postgrad. Med. 122(3), 16-27 (2010).
15. TM, package insert. Bristol-Myers Squibb, Princeton, NJ, USA &AstraZeneca, Wilmington, DE, USA.
16. Rosenstock J, Aguilar-Salinas C, Klein E et al. Effect of saxagliptin monotherapy in treatment-naive patients with Type 2 diabetes. Curr. Med. Res. Opin. 25(10), 2401-2411 (2009).
17. Jadzinsky M, Pfützner A, Paz-Pacheco E et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with Type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes. Metab. 11(6), 611-622 (2009).
18. Chacra AR, Tan GH, Apanovitch A et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with Type 2 diabetes: a randomised controlled trial. Int. J. Clin. Pract. 63(9), 1395-1406 (2009).
19. Hollander P, Li J, Allen E, Chen R; for the CV181-013 investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with Type 2 diabetes and inadequate control on thiazolidinedione alone. J. Clin. Endocrinol. Metab. 94(12), 4810-4819 (2009).
20. DeFronzo RA, Hissa M, Garber AJ et al. The effcacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled Type 2 diabetes on metformin alone. Diabetes Care 32(9), 1649-1655 (2009).
21. Augeri DJ, Robl JA, Betebenner DA et al Discovery and preclinical profle of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. J. Med. Chem. 48(15), 5025-5037 (2005).
22. Metzler WJ, Yanchunas J, Weigelt C et al. Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. Protein Sci. 17(2), 240-250 (2008).
23. Kirby M, Yu DM, O'Connor SP, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin. Sci. 118(1), 31-41 (2010).
24. Drucker DJ. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 117(1), 24-32 (2007).
25. Kirby MS, Dorso C, Wang A et al. In vitro enzymologic characteristics of saxagliptin, a highly potent and selective DPP4 inhibitor with 'slow binding' characteristics. Clin. Chem. Lab. Med. 46, (2008) (Abstract A29).
26. Johnson KM. Dutogliptin, a dipeptidyl peptidase inhibitor for the treatment of Type 2 diabetes mellitus. Curr. Opin. Investig. Drugs 11(4), 55-463 (2010).
27. Boulton D, Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in Type 2 diabetic and healthy subjects. Diabetes 56(Suppl. 1), (2007) (Abstract 606P).
28. Ban K, Noyan-Ashraf MH, Hoefer J et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 117(18), 2340-2350 (2008).
29. Patel CG, Zhang J, Li L et al. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects. J. Clin. Pharmacol. 50(10), 1211-1216. (2010).
30. Boulton DW, Li L, Frevert EU et al. Infuence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin. Pharmacokinet. (In press).
31. Patel C, Komoroski B, Brenner E, Li L, Boulton D. No meaningful pharmacokinetic drug-drug interactions between saxagliptin and metformin in healthy subjects. Presented at: American College of Clinical Pharmacy. Denver, CO, USA, 14-17 October 2007.
32. Patel C, Komoroski B, Li L, Boulton D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and glyburide in healthy subjects. Presented at: American College of Clinical Pharmacy. Denver, CO, USA, 14-17 October 2007.
33. Patel CG, Wolf RA, Komoroski B, Li L, Boulton AJ. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and pioglitazone in healthy subjects. Presented at: American College of Clinical Pharmacy. Denver, CO, USA, 14-17 October 2007.
34. Boulton DW, Li L, Patel CG. No pharmacokinetic interaction between saxagliptin and digoxin in healthy subjects. Clin. Pharmacol. Ther. 83(Suppl. 1), S93 (2008) (Abstract PIII-69).
35. Boulton DW, Adams D, Li L et al. Maalox max, famotidine or omeprazole do not meaningfully affect the pharmacokinetics of saxagliptin in healthy subjects. Clin. Pharmacol. Ther. 83(Suppl. 1), S92 (2008).
36. Patel CG, Boulton DW, Brenner E. Effect of ketoconazole on the pharmacokinetics of saxagliptin in healthy subjects. J. Clin. Pharmacol. 47, 1183-1211 (2007) (Abstract 89).
37. Onglyza™ Europe, package insert. Bristol-Myers Squibb, Princeton, NJ, USA, & AstraZeneca, Wilmington, DE, USA.
38. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with Type 2 diabetes. Diabetes Obes. Metab. 10, 376-386 (2008).
39. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of Type 2 diabetes mellitus. Adv. Ther. 26(3), 249-262 (2009).
40. DeFronzo R, Hissa MN, Garber AJ et al. Once daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D. Diabetes 58(Suppl. 1), (2009) (Abstract 547-P).
41. Maheux P, Doucet J, Allen E et al. Effcacy and safety of saxagliptin 5 mg once-daily therapy in elderly patients with Type 2 diabetes mellitus. Diabetologia 52, 1-550 (2008).
42. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fuid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27(1), 256-263 (2004).
43. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with Type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes. Metab. 9(2), 166-174 (2007).
44. Chen R, Donovan M, Rusnak JM. Saxagliptin used as monotherapy or in combination with other antihyperglycemic agents does not signifcantly increase risk of hypoglycemia. Diabetes 58(Suppl. 1), A536 (2009).
45. Hermansen K, Kipnes M, Luo E et al. Effcacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with Type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes. Metab. 9(5), 733-745 (2007).
46. Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with Type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab. 10(11), 1047-1056 (2008).
47. US Department of Health and Human Services. Food and Drug Administration. FDA Approval 22-350. June (2008).
48. Patel C, Castaneda L, Frevert U et al. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects. Diabetes 57(Suppl. 1), (2008) (Abstract A160).
49. Scheen AY, Charpentier G, Östgren CJ, Hellqvist Å, Gause-Nilsson I. Effcacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with Type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 26(7), 540-549 (2010).
50. Hinke SA, Kühn-Wache K, Hoffmann T et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem. Biophys. Res. Commun. 291(5), 1302-1308 (2002).
51. DeFronzo RA, Okerson T, Viswanathan P et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin. 24(10), 2943-2952 (2008).
52. Vella A, Bock G, Giesler PD et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in Type 2 diabetes. Diabetes 56(5), 1475-1480 (2007).